Imunon Reports Strong Enrollment Momentum In Phase 3 Ovation 3 Trial Of Imnn-001 In Advanced Ovarian Cancer
IMNN•Phase 3 Ovation 3 enrollment momentum
July 30 (Reuters) - Imunon Inc IMNN.O:
- Imunon reports strong enrollment momentum in Phase 3 Ovation 3 trial of IMNN-001 in advanced ovarian cancer
- Imunon reports enrollment rate exceeding forecast in Ovation 3 trial
- Imunon projects enrollment completion in Q2 2029 for Ovation 3 trial
- Imunon says IMNN-001 demonstrates favorable safety profile with no serious immune-related adverse events
